Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovati ...
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
Accessing PHI for development and testing is often blocked by stringent HIPAA compliance requirements. Learn how synthetic data helps engineers build tools to close care gaps and improve HEDIS scores.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results